MDXXF (Pharmala Biotech Holdings) Total Assets: $2.29 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.11
GF Value $0.15
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Total Assets?

Pharmala Biotech Holdings MDXXF +0.44% 33 Total Assets is $2.29 Mil as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Pharmala Biotech Holdings's Total Assets for the quarter that ended in Feb. 2026 was $2.29 Mil.

During the past 12 months, Pharmala Biotech Holdings's average Total Assets Growth Rate was 7.10% per year. During the past 3 years, the average Total Assets Growth Rate was 18.50% per year.

During the past 5 years, Pharmala Biotech Holdings's highest 3-Year average Total Assets Growth Rate was 97.50%. The lowest was 18.50%. And the median was 58.00%.

Total Assets is connected with ROA %. Pharmala Biotech Holdings's annualized ROA % for the quarter that ended in Feb. 2026 was -42.11%. Total Assets is also linked to Revenue through Asset Turnover. Pharmala Biotech Holdings's Asset Turnover for the quarter that ended in Feb. 2026 was 0.09.

Pharmala Biotech Holdings  (OTCPK:MDXXF) Total Assets Explanation

Total Assets is connected with ROA %.

Pharmala Biotech Holdings's annualized ROA % for the quarter that ended in Feb. 2026 is

ROA %=Net Income (Q: Feb. 2026 )/( (Total Assets (Q: Nov. 2025 )+Total Assets (Q: Feb. 2026 ))/ count )
=-0.992/( (2.418+2.293)/ 2 )
=-0.992/2.3555
=-42.11 %

Note: The Net Income data used here is four times the quarterly (Feb. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Pharmala Biotech Holdings's Asset Turnover for the quarter that ended in Feb. 2026 is

Asset Turnover
=Revenue (Q: Feb. 2026 )/( (Total Assets (Q: Nov. 2025 )+Total Assets (Q: Feb. 2026 ))/ count )
=0.206/( (2.418+2.293)/ 2 )
=0.206/2.3555
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Pharmala Biotech Holdings Total Assets Related Terms

Pharmala Biotech Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Total Assets Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Total Assets
2.22 1.80 1.79 2.12 2.48

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 2.62 2.48 2.42 2.29
MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Pharmala Biotech Holdings's Total Assets for the fiscal year that ended in Aug. 2025 is calculated as

Total Assets=Total Equity (A: Aug. 2025 )+Total Liabilities (A: Aug. 2025 )
=1.782+0.697
=2.48

Pharmala Biotech Holdings's Total Assets for the quarter that ended in Feb. 2026 is calculated as

Total Assets=Total Equity (Q: Feb. 2026 )+Total Liabilities (Q: Feb. 2026 )
=1.58+0.713
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $2.29 Mil mean?
Pharmala Biotech Holdings (MDXXF) has a Total Assets of $2.29 Mil as of Feb. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' Total Assets too high?
Pharmala Biotech Holdings' current Total Assets is $2.29 Mil. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Total Assets compare to VRTX and REGN?
Pharmala Biotech Holdings' Total Assets of $2.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current Total Assets is $2.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 29.2% below its estimated fair value. The current Total Assets is $2.29 Mil. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Total Assets is $2.29 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 29.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • Total Assets: $2.29 Mil
  • GF Value™: $0.15 vs. price of $0.11 (29.2% below fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value